A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment

Eur Respir J. 2015 Feb;45(2):554-7. doi: 10.1183/09031936.00142914. Epub 2014 Oct 30.

Authors

Akos Somoskovi¹, Vera Bruderer², Rico Hömke³, Guido V Bloemberg², Erik C Böttger³

Affiliations

¹ Institut für Medizinische Mikrobiologie, Universität Zürich, Zurich, Switzerland Nationales Referenzzentrum für Mykobakterien, Universität Zürich, Zurich, Switzerland akossomos@yahoo.com.
² Institut für Medizinische Mikrobiologie, Universität Zürich, Zurich, Switzerland.
³ Institut für Medizinische Mikrobiologie, Universität Zürich, Zurich, Switzerland Nationales Referenzzentrum für Mykobakterien, Universität Zürich, Zurich, Switzerland.

PMID: 25359333
DOI: 10.1183/09031936.00142914

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antitubercular Agents / administration & dosage*
Clofazimine / administration & dosage*
Diarylquinolines / administration & dosage*
Drug Resistance, Bacterial / genetics*
Humans
Microbial Sensitivity Tests
Mutation*
Mycobacterium tuberculosis / genetics
Phenotype
Quinolines / administration & dosage
Treatment Outcome
Tuberculosis, Multidrug-Resistant / drug therapy*

Substances

Antitubercular Agents
Diarylquinolines
Quinolines
bedaquiline
Clofazimine